Phase i trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion

Journal of Thoracic Oncology

Volumn 5, Issue 1, 2010, Pages 75-81

  Jones, David R ^a   Taylor, Matthew D ^a   Petroni, Gina R ^b   Shu, Jianfen ^b   Burks, Sandra G ^a   Daniel, Thomas M ^a   Gillenwater, Heidi H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Intrapleural chemotherapy; Malignant pleural effusion

Indexed keywords

DOCETAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DRUG FEVER; DRUG HALF LIFE; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IMPLANT; INFECTION; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; STOMATITIS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 76149141215     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c07ddc     Document Type: Article

References (39)

1. Martinez-Moragon E, Aparicio J, Sanchis J, Menéndez R, Cruz Rogado M, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998;65:108-113.
2. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977;63:695-702.
3. van de Molengraft FJ, Vooijs GP. Survival of patients with malignancyassociated effusions. Acta Cytol 1989;33:911-916.
4. Monte SA, Ehya H, Lang WR. Positive effusion cytology as the initial presentation of malignancy. Acta Cytol 1987;31:448-452.
5. Lynch TJ Jr. Management of malignant pleural effusions. Chest 1993; 103:385S-389S.
6. Aelony Y, King RR, Boutin C. Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH. Chest 1998;113:1007-1012.
7. Cheng D, Chan YM, Ng TY, Cheung AN, Ngan HY, Wong LC. Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological cancer. Acta Obstet Gynecol Scand 1999;78:443-446.
8. Ong KC, Indumathi V, Raghuram J, Ong YY. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology 2000;5:99-103.
9. Chella A, Ribechini A, Dini P, Adamo C, Mussi A, Angeletti CA. [Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis.] Minerva Chir 1994;49:1077-1082.
10. Rosso R, Rimoldi R, Salvati F, et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988;45:253-256.
11. Lissoni P, Mandala M, Curigliano G, et al. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. Oncology 2001;60:308-312.
12. Senyigit A, Bayram H, Babayigit C, Topçu F, Balci AE, Satici O. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases. Respiration 2000;67:623-629.
13. Ren S, Terman DS, Bohach G, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 2004;126:1529-1539.
14. Uehara T, Yano T, Kuninaka S, Yoshino I, Asoh H, Ichinose Y. The influence of enhanced postoperative inflammation by the intrapleural administration of streptococcal preparation (OK-432) on the prognosis of completely resected non-small-cell lung cancer. J Surg Oncol 2000; 75:51-54.
15. Yoshida K, Sugiura T, Takifuji N, et al. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 2007;58:362-368.
16. Shimizu T, Takahashi N, Terakado M, Akusawa H, Tsujino I, Horie T. Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients. Intern Med 2006;45:715-720.
17. Ishida A, Miyazawa T, Miyazu Y, et al. Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer. Respirology 2006;11:90-97.
18. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999;86:1992-1999.
19. Martinez-Moragon E, Aparicio J, Rogado MC, Sanchis J, Sanchis F, Gil-Suay V. Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 1997;10:2380-2383.
20. Hatta T, Tsubota N, Yoshimura M, Yanagawa M. [Intrapleural minocycline for postoperative air leakage and control of malignant pleural effusion.] Kyobu Geka 1990;43:283-286.
21. Figlin R, Mendoza E, Piantadosi S, Rusch V. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861. Chest 1994;106:363S-366S.
22. Masuno T, Kishimoto S, Ogura T, et al. A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer. Cancer 1991;68:1495-1500.
23. Tohda Y, Iwanaga T, Takada M, et al. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 1999;45:197-204.
24. Shoji T, Tanaka F, Yanagihara K, Inui K, Wada H. Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest 2002;121:821-824.
25. Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang-Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anticancer Drugs 1997;8:565-573.
26. Lerza R, Vannozzi MO, Tolino G, et al. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol 1997;8:385-391.
27. Bogliolo GV, Lerza R, Bottino GB, et al. Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer 1991;27:839-842.
28. Muraoka M, Oka T, Akamine S, et al. Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion. J Surg Oncol 2006;93:323-329.
29. Ichinose Y, Tsuchiya R, Koike T, et al. A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical intervention. J Thorac Cardiovasc Surg 2002;123:695-699.
30. Rusch VW, Figlin R, Godwin D, Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusion: a Lung Cancer Study Group trial. J Clin Oncol 1991;9:313-319.
31. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, Inc., 1982.
32. Rinaldo JE, Owens GR, Rogers RM. Adult respiratory distress syndrome following intrapleural instillation of talc. J Thorac Cardiovasc Surg 1983;85:523-526.
33. Factor SM. Granulomatous pneumonitis. A result of intrapleural instillation of quinacrine and talcum powder. Arch Pathol 1975;99:499-502.
34. Bouchama A, Chastre J, Gaudichet A, Soler P, Gibert C. Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. Chest 1984;86:795-797.
35. Belani CP, Pajeau TS, Bennett CL. Treating malignant pleural effusions cost consciously. Chest 1998;113:78S- 85S.
36. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994;120:56-64.
37. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985;12:54-75.
38. Perng RP, Chen YM, Wu MF, et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med 1998;92:473-479.
39. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol 1992;10:1485-1491.